11 news items
Beyond The Numbers: 4 Analysts Discuss Gritstone Bio Stock
GRTS
13 May 24
Outperform
$4.00
-
Key Insights:
Action Taken: In response to dynamic
Gritstone bio Reports First Quarter 2024 Financial Results and Provides Corporate Updates
GRTS
9 May 24
findings showing induction of broad and durable immune responses through 12 months. HIV – Collaboration with Gilead under
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gritstone bio, Inc. - GRTS
GRTS
24 Apr 24
cancer vaccine candidate Granite, including a short-term response analysis that did not demonstrate a difference between study arms. In discussing
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gritstone bio, Inc. - GRTS
GRTS
20 Apr 24
response analysis that did not demonstrate a difference between study arms. In discussing these results, Gritstone's Chief Executive Officer
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gritstone bio, Inc. - GRTS
GRTS
16 Apr 24
candidate Granite, including a short-term response analysis that did not demonstrate a difference between study arms. In discussing these results
ov0x78027ik359zfaaudhq3i016np1bu8jc c38kg24k6w70
GRTS
12 Apr 24
personalized cancer vaccine candidate Granite, including a short-term response analysis that did not demonstrate a difference between study arms
8t3cv5di70zzny7qy8ojpgi0itytndrg9raktdbafkhpbr 6qyp
GRTS
8 Apr 24
candidate Granite, including a short-term response analysis that did not demonstrate a difference between study arms. In discussing these results
7bq6b5x1v9l
GRTS
4 Apr 24
, 2024, Gritstone reported mixed preliminary Phase 2 data for its personalized cancer vaccine candidate Granite, including a short-term response
zy47uat86mt0pjrx48m9
GRTS
2 Apr 24
shows the expected relationship with disease progression and favors GRANITE, while short-term ctDNA response analysis did not demonstrate a difference
nd7n060ycfat5f690lct19eyfs1ymwfbybsg3o9rhns46gi4u3vf1
GRTS
1 Apr 24
-1.38]; 44% censored); >90% of high-risk patients have liver metastases -- -- Short-term molecular response
eau4d846
GRTS
5 Mar 24
in whole or in part with federal funds from the Department of Health and Human Services; Administration for Strategic Preparedness and Response; Biomedical
- Prev
- 1
- Next